Kepler Cheuvreux Suisse SA acquired a new position in Pfizer Inc. (NYSE:PFE) during the third quarter, purchasing 651,996 shares valued at approximately $16.61 million. This comes amidst varied sentiment surrounding Pfizer, with positive news from a Phase-2 readout for an eczema drug and FDA approval for a rare genetic condition treatment, but also concerns about the company’s payout ratio and a recent quarterly loss. Analysts have mixed ratings on PFE, with a consensus “Hold” and an average price target of $28.05.
651,996 Shares in Pfizer Inc. $PFE Bought by Kepler Cheuvreux Suisse SA
Kepler Cheuvreux Suisse SA acquired a new position in Pfizer Inc. (NYSE:PFE) during the third quarter, purchasing 651,996 shares valued at approximately $16.61 million. This comes amidst varied sentiment surrounding Pfizer, with positive news from a Phase-2 readout for an eczema drug and FDA approval for a rare genetic condition treatment, but also concerns about the company’s payout ratio and a recent quarterly loss. Analysts have mixed ratings on PFE, with a consensus “Hold” and an average price target of $28.05.